Literature DB >> 15737691

Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors.

Tomonori Takahashi1, Zhenghua Min, Iichiro Uchida, Michitsune Arita, Yoh Watanabe, Minoru Koi, Hiromichi Hemmi.   

Abstract

We studied the cytotoxic effects of various DNA replication inhibitors on MMR-deficient and -proficient colon carcinoma cell lines. DNA polymerase (pol) inhibitors including aphidicolin and gemcitabine, and hydroxyurea were more toxic (1.7 to 2.8-fold) to hMLH1-deficient HCT116 than to hMLH1-proficient HCT116+ch3. Similarly, pol inhibitors were more toxic to hMSH2-deficient LoVo than to hMSH2-proficient LoVo+ch2. In contrast, DNA topoisomerase I inhibitors, such as CPT-11, SN-38, and topotecan, were more toxic to MMR-proficient cells. Our results suggest that MMR-deficient colon carcinoma cells are hypersensitive to inhibitors of the pol reaction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737691     DOI: 10.1016/j.canlet.2004.07.044

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects.

Authors:  Zhiyun He; Dharmalingam Subramaniam; Satish Ramalingam; Animesh Dhar; Russell G Postier; Shahid Umar; Youcheng Zhang; Shrikant Anant
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

2.  Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.

Authors:  Yoh Watanabe; Eiji Koike; Hidekatsu Nakai; Tomomaro Etoh; Hiroshi Hoshiai
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

3.  CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

Authors:  Lorraine Pelosof; Sashidhar R Yerram; Nita Ahuja; Andrew Delmas; Ludmila Danilova; James G Herman; Nilofer S Azad
Journal:  Int J Cancer       Date:  2013-08-24       Impact factor: 7.396

4.  Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.

Authors:  Mandar Ramesh Bhonde; Marie-Luise Hanski; Jenny Stehr; Britta Jebautzke; Roser Peiró-Jordán; Henry Fechner; Kazunari Kazushige Yokoyama; Weei-Chin Lin; Martin Zeitz; Christoph Hanski
Journal:  Int J Cancer       Date:  2010-06-15       Impact factor: 7.396

5.  DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response.

Authors:  Rachel A Freiberg; Ester M Hammond; Mary Jo Dorie; Scott M Welford; Amato J Giaccia
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

Review 6.  Mismatch repair deficient colorectal cancer in the era of personalized treatment.

Authors:  Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-02-23       Impact factor: 66.675

7.  Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress.

Authors:  M Hewish; S A Martin; R Elliott; D Cunningham; C J Lord; A Ashworth
Journal:  Br J Cancer       Date:  2013-01-29       Impact factor: 7.640

8.  TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs.

Authors:  Shar-yin N Huang; Junko Murai; Ilaria Dalla Rosa; Thomas S Dexheimer; Alena Naumova; William H Gmeiner; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2013-06-17       Impact factor: 16.971

9.  A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.

Authors:  Marina Baretti; Enusha Karunasena; Marianna Zahurak; Rosalind Walker; Yang Zhao; Thomas R Pisanic; Tza-Huei Wang; Tim F Greten; Austin G Duffy; Elske Gootjes; Gerrit Meijer; Henk M W Verheul; Nita Ahuja; James G Herman; Nilofer S Azad
Journal:  Clin Transl Sci       Date:  2021-04-03       Impact factor: 4.689

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.